Copy

In this Issue of LBCA News:
An Important Message from Our Founder
 



A Message from Founder Leigh Pate

LBCA Founder Leigh Pate reflects on the 2017 launch of the organization, introduces the new generation of leadership that will continue to guide the organization on its mission, and how to help support LBCA's future work. 
Hear from LBCA's Executive Director

 
A Message from Executive Director Laurie Hutcheson
 
Executive Director Laurie Hutcheson is excited to share LBCA and ILC successes and advances, its updated Mission, Vision, and goals, and where the organization is headed in the future. 

 

Find Out More About the Work of our Scientific Advisory Board Members
LBCA's Scientific Advisory Board Is Tackling ILC through Research
 
The Lobular Breast Cancer Alliance keeps its invasive lobular carcinoma (ILC) information and research cutting edge with the guidance of a Scientific Advisory Board (SAB) of clinicians and scientists spanning the US and Europe who are experts in and committed to ILC research and treatment. Read more about their  current work.
Check Out Eight New Studies in the LBCA Research Library
LBCA's ILC Research Library is always being updated with ithe most important and current studies. Eight new studies have recently been added to the collection. 
Dr. Maxine Jochelson Presents on Contrast Enhanced Mammography (CEM)
Heard at Lynn Sage
 Contrast Enhanced Mammography to Be Assessed for Utility As MRI Alternative in Detecting Tumors 

 
Dr. Maxine Jochelson is the Director of Imaging at the Evelyn Lauder Breast and Imaging Center at Memorial Sloan Kettering Cancer Center where she is also an Attending Radiologist and a Clinical Professor of Radiology at Cornell Weill Medical School.
On September 11, she presented an Update on Contrast Enhanced Mammography at the 22d Annual Lynn Sage virtual Breast Cancer Symposium. She discussed its potential as an effective and less expensive method for detecting breast cancer, including ILC, than MRI, and an upcoming large scale trial that will evaluate it. 
Study Lead Author and SAB Member Provide Commentaries on Newly Released Research

New ILC Research:
 What it Means and Its Potential Impact

In August, Breast Cancer Research published the study Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. One of the study's lead authors, Simon Johnston, PhD, MBBS, provides a summary of the study while LBCA Scientific Advisory Board member Rachel Jankowitz  on the clinical impact of the findings.
 
Copyright © 2020 Lobular Breast Cancer Alliance (LBCA) - a project of Social and Environmental Entrepreneurs, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
View LBCA's privacy policy and terms of service on our website.

View this email in your browser

Email Marketing Powered by Mailchimp
LBCA on Facebook
LBCA on Facebook
LBCA on Twitter
LBCA on Twitter
LobularBreastCancer.org
LobularBreastCancer.org